Semax: The Nootropic Peptide from ACTH Research
Semax is a synthetic heptapeptide derived from the adrenocorticotropic hormone (ACTH) fragment 4-10, with a modified C-terminal Pro-Gly-Pro sequence that enhances stability and biological activity. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s by Nikolai Myasoedov and colleagues, Semax has been extensively studied for its neuroprotective and nootropic properties (Ashmarin et al., 1995).
Semax received regulatory approval in Russia and several CIS countries as a prescription medication for conditions including cognitive impairment and stroke recovery, making it one of the most clinically advanced nootropic peptides in research.
Molecular Profile
- Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (ACTH 4-10 analog with PGP extension)
- Amino acids: 7 (heptapeptide)
- Molecular weight: ~813.97 Da
- CAS number: 80714-61-0
- Parent molecule: ACTH (adrenocorticotropic hormone), fragment 4-10
- Modification: C-terminal Pro-Gly-Pro stabilizing sequence
- Administration route studied: Intranasal (primary), subcutaneous
Mechanism of Action
Unlike full-length ACTH, Semax does not stimulate adrenal cortisol production. The 4-10 fragment retains the neurotropic properties of ACTH while lacking its steroidogenic effects. Semax's documented mechanisms include (Levitskaya et al., 2008):
- BDNF upregulation: Semax increases expression of brain-derived neurotrophic factor, a key mediator of neuronal survival, growth, and synaptic plasticity
- TrkB receptor activation: BDNF-mediated activation of the TrkB receptor pathway, downstream of which lie neuroprotective signaling cascades
- Dopaminergic and serotonergic modulation: Effects on monoamine neurotransmitter systems involved in attention, motivation, and mood regulation
- Anti-inflammatory neuroprotection: Reduction of pro-inflammatory cytokines in brain tissue following ischemic injury
Research Area 1: BDNF and Neurotrophic Factor Expression
Dolotov et al. (2006) demonstrated that Semax significantly increased BDNF mRNA expression in rat brain hippocampus and cortex within hours of administration. This upregulation of BDNF is considered a primary mechanism underlying Semax's neuroprotective and pro-cognitive effects, as BDNF plays essential roles in long-term potentiation (LTP), memory consolidation, and neuronal survival.
Agapova et al. (2007) confirmed that Semax also upregulated nerve growth factor (NGF) and BDNF in rat basal forebrain neurons, suggesting broad neurotrophic factor modulation rather than BDNF-specific effects.
Research Area 2: Stroke and Cerebral Ischemia
Significant clinical research has examined Semax in ischemic stroke contexts. Gusev et al. (1997) conducted clinical studies in acute ischemic stroke patients, reporting improved neurological outcomes and accelerated recovery in Semax-treated groups compared to standard care. The researchers attributed the effects to neuroprotection during the acute ischemic period.
Medvedev et al. (2006) studied Semax's effects on gene expression in ischemic rat brain tissue and identified modulation of over 50 genes involved in inflammation, apoptosis, and neurotransmission, providing a molecular profile of its neuroprotective mechanisms.
Dergunova et al. (2008) further characterized the transcriptomic response to Semax during ischemia, identifying upregulation of anti-apoptotic genes and suppression of inflammatory cascades as key neuroprotective mechanisms.
Research Area 3: Cognitive Enhancement
Semax's effects on cognitive function have been studied across multiple paradigms. Glazova et al. (2005) demonstrated that Semax improved learning and memory in rat behavioral models, including the Morris water maze and passive avoidance tasks. The cognitive enhancement was associated with increased hippocampal BDNF levels and enhanced long-term potentiation.
Eremin et al. (2005) studied Semax in conditions of chronic stress-induced cognitive impairment in rodents. The peptide protected against stress-related memory deficits and attenuated the elevation of corticosterone that typically accompanies chronic stress, despite lacking direct adrenal effects.
Research Area 4: Attention and ADHD Research
Semax has been studied in attention-related contexts. Ershov et al. (2006) investigated Semax's effects on attention performance in clinical studies, reporting improvements in sustained attention and information processing speed. The mechanisms were attributed to modulation of dopaminergic and noradrenergic systems involved in attentional control.
The peptide's effects on catecholamine neurotransmission, particularly dopamine turnover in prefrontal cortex regions, have made it a compound of interest in attention-deficit research paradigms.
Research Area 5: Optic Nerve and Neurodegeneration
Semax has been studied for its neuroprotective effects in optic nerve pathology. Gavrilova et al. (2010) investigated Semax in patients with optic nerve atrophy and reported improvements in visual function parameters, suggesting neurotrophic support for retinal ganglion cells and optic nerve fibers.
These findings extend the peptide's neuroprotective profile beyond cerebral neurons to include retinal and optic nerve tissue, consistent with its broad neurotrophic factor upregulation mechanism.
Current Research Status
Semax is one of the most well-studied nootropic peptides, with a clinical use history spanning several decades in Russia. International research interest has grown, particularly in the areas of neurotrophic factor modulation and stroke neuroprotection. The compound's favorable safety profile, documented BDNF-enhancing effects, and established clinical track record make it a foundational reference compound in nootropic peptide research.
Research Disclaimer
This article is for educational and informational purposes only. BeaCapra supplies research peptides for laboratory and research use. Nothing in this article constitutes medical advice.